Introduction
Allogeneic BM transplantation (BMT) remains to be limited by morbidity and mortality related to graft-versus-host disease (GVHD). [1] [2] [3] [4] [5] GVHD is caused by donor T cells that recognize and react to histocompatibility differences between the donor and host. [1] [2] [3] [4] [5] It occurs in three sequential characteristic phases: priming, induction and effector phase. 1, [3] [4] [5] During the priming phase, host antigen-presenting cells (APCs) elicit initial activation and proliferation of donor T cells. 1, [3] [4] [5] [6] During the induction phase, activated donor T cells undergo robust proliferation and differentiation into effector cells. 1, 2, 6, 7 The effector phase is characterized by migration and infiltration of alloreactive effector cells into GVHD target organs, causing host tissue injury.
1, 2, [5] [6] [7] Histone methylation, which is catalyzed by histone methyltransferanses (HMT), has been correlated with the expression of genes associated with proliferation, differentiation and survival of Ag-activated T cells. 8, 9 We have recently demonstrated that inhibition of histone methylation using 3-Deazaneplanocin A (DZNep) arrested ongoing GVHD through induction of apoptosis in alloreactive T cells. 10 DZNep reduced multiple histone methylation marks, including trimethylation of histone H3 at lysine 4 (H3K4me3), H3K27me3, H3K36me3 and H4K20me3, 10- 12 each of which is catalyzed by a specific HMT. 9, 13 However, the key HMT that regulates allogeneic T cell responses remains unclear.
Ezh2 is a HMT that catalyzes H3K27me3 and acts primarily as a gene silencer. 14 Ezh2 controls cell proliferation, differentiation and function in numerous contexts. 14 Ezh2 can influence proliferation and differentiation of hematopoietic stem cells, 15, 16 B lymphopoiesis 17 and
For personal use only. on May 30, 2017 . by guest www.bloodjournal.org From thymopoiesis. 16 Naïve T cells expressed low levels of Ezh2 but rapidly upregulated Ezh2 upon TCR-ligation and alloantigen-stimulation. 10, 16, 18 However, whether Ezh2 plays important roles in regulating T-cell immune responses in vivo has not been previously determined. In the present study, we used conditional inactivation models to isolate the stage-specific alterations in allogeneic T cell responses engendered by Ezh2 ablation, and its effect on GVHD and graftversus-leukemia (GVL) activity.
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Materials and Methods
Our data regarding experimental mice, antibodies (Abs), flow cytometry analysis, cell lines, cell preparation, culture of T cells, cytotoxicity assay, BMT and induction of GVHD, induction of GVL, in vivo bioluminescence imaging, enzyme-linked immunosorbent assay (ELISA), realtime reverse transcription polymerase chain reaction (RT-PCR), and chromatin immunoprecipitation assay (ChIP) are detailed in supplemental files. Experimental protocols were approved by the University of Michigan's Committee on Use and Care of Animals.
Statistical analysis.
Survival in different groups was compared by using the log-rank test.
Comparison of two means was analyzed by using the two-sided two-sample T-test.
RESULTS

Conditional loss of Ezh2 in donor T cells inhibits acute GVHD
To inactivate the enzyme activity of Ezh2 in mature T cells, we bred mice with floxed alleles of Ezh2 (Ezh2 fl/fl ) 17 to B6 mice expressing Cre recombinase under control of the CD4
promoter to generate T cell-specific Ezh2 conditional knockout B6 mice (named T-KO). In agreement with previous observations, 16 the absence of Ezh2 had no significant effect on the percentage and number of double negative (DN), double positive (DP), and CD4 + and CD8 + single positive (SP) thymocytes (Supplemental Fig.1A ). Likewise, normal absolute numbers and phenotype (e.g., CD25, CD44, CD69 and CD62L) of T cells were found in the spleen and lymph nodes (LN) of T-KO and wild type (WT) mice (Supplemental Fig.1B, C) . Western blot confirmed the deletion of Ezh2 (Fig.1A) and reduction of H3K27me3 in T-KO T cells (Fig.1B) .
We then examined the impact of Ezh2 ablation in allogeneic T cells using the major histocompatibility (MHC)-mismatched B6 anti-BALB/C mouse GVHD model. Lethally irradiated BALB/C mice were transplanted with T cell depleted (TCD) BM from B6 mice with or without WT or T-KO T cells. As expected, WT T cell recipients died from GVHD. In contrast,
T-KO T cell recipients did not develop clinical signs of severe GVHD and all survived (Fig.1C) .
Histological examination showed a significant reduction of inflammation in the intestine, skin and liver of T-KO T cell recipients (Fig.1D, E ). In addition, as compared to TCD BM recipients,
T-KO T cell recipients showed complete donor BM engraftment in the BM, spleen, thymus and peripheral blood (Supplemental Fig.2 
), suggesting that T-KO T cells do not impair hematopoietic
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Ezh2 plays a differentiation stage-specific role in alloantigen-driven T cells
To understand the mechanism by which Ezh2-deficient T cells failed to induce GVHD, we first determined whether loss of Ezh2 impaired activation, engraftment and/or proliferation of donor T cells during the GVHD priming phase. By 3 days after transplantation, there was no significant difference in numbers of donor-derived T cells in the spleen in BALB/C recipients of T-KO T cells compared with WT T cells, with modestly increased numbers of donor CD8 + T cells ( Fig.2A) . When carboxyfluorescein diacetate succinimidyl ester (CFSE) was used to track cell division, T-KO T cells had slightly higher percentages of dividing cells than WT T cells (Fig.2B ).
Furthermore, both T-KO and WT T cells expressed high levels of activation markers (e.g., CD25, CD44, CD69 and CD122) (Fig.2C) . To assess proliferation of T-KO T cells in response to alloantigens, we assessed the BrdU incorporation by donor T cells three days after in vitro stimulation with allogeneic dendritic cells (DCs). There was no difference in BrdU + percentage between activated WT and T-KO T cells (Fig.2D ). We further examined the effect of Ezh2 deficiency on TCR signaling in T cells and showed normal activation of AKT and ERK signaling intermediates in T-KO T cells (Supplemental Fig.3 ). These results suggest successful activation and proliferation of T-KO T cells during priming phase.
To evaluate whether Ezh2 deficiency affected alloreactive T cells at later stages, we tracked donor-derived T cells in the spleen of BALB/C recipients during the GVHD induction phase. By day 7 post-transplantation, the number of rapidly dividing T-KO CD4 + T cells (i.e., more than 7
For personal use only. on May 30, 2017 . by guest www.bloodjournal.org From rounds of cell division) was markedly reduced (Fig.3A) . T-KO CD4 + T cells showed increased apoptosis compared to WT cells (Fig.3B) . As a result, there was an overall reduction in the total number of donor CD4 + T cells in the spleen, liver, BM and intestine of BALB/C recipients at day 7 and 14 after transplantation (Fig.3C ). BrdU incorporation assay showed the reduced proliferation of T-KO CD4 + T cells 5 days after allogeneic DC stimulation (Fig.3D) . Similar results were observed for T-KO CD8 + T cells (Supplemental Fig.4A-D) .
In GVHD models, alloantigen-specific T cell proliferation occurs in parallel to homeostatic proliferation in irradiated hosts. 21, 22 To assess the effect of Ezh2 deficiency on alloantigen-driven (Fig.4A ). Seven days after transplantation, total numbers of T-KO Treg cells were markedly reduced compared to WT cells (Fig.4A) . To evaluate the function (Fig.4D ). These data demonstrate that Ezh2 is intrinsically required to regulate the survival and expansion of alloantigen-activated T cells.
Deletion of Bim minimally rescues alloantigen-activated T cells lacking Ezh2
Having observed an increase of apoptosis in T-KO cells ( 
Ezh2-deficient T cells are specifically impaired in their induction of IFN-γ-producing effector cells
As a gene silencer, Ezh2 has been thought to repress T cell production of IFN-γ, IL-4 and IL-17. 27, 28 Previous studies demonstrate that IFN-γ-producing alloreactive T help (Th)1 effector cells cause damage to the liver and gastrointestinal tract, but prevents lung injury mainly induced by IL-4-producing Th2 effector cells. 29, 30 To investigate the impact of Ezh2 on effector T cell differentiation, we recovered donor T cells from BALB/C mice receiving B6 mouse-derived WT and T-KO T cells at various time points after transplantation. There was no significant difference in percentage of IFN-γ-producing CD4 + T cells between WT and T-KO T cell recipients 3 days after transplantation (Fig.6A ), consistent with a successful activation of T-KO T cells (Fig.2) . In contrast, 7 and 14 days after transplantation, T-KO CD4 + T cells showed markedly reduced frequency of IFN-γ + effector cells than WT CD4 + T cells (Fig.6A) . ELISA confirmed the decreased secretion of IFN-γ by these T-KO CD4 + T cells (Fig.6B) .
Reduction of T-KO IFN-
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Similar results were observed for alloantigen-activated T-KO CD8 + T cells (Supplemental Fig.8 ).
Loss of Ezh2 led to increased overall production of IL-4 in alloreactive T cells (Fig.6B) without polarizing into a clearly distinguishable Th2 population 7 days after transfer (Fig.6C) . Gata3 (Fig.6E ). Th17 cell differentiation involves activation of Stat3 and RORγt. 31 Loss of Ezh2 did not alter the expression of Il17 and Rorγt transcripts (Fig.6E) .
through a mechanism of stimulating expression of Ifng, Tbx21 and Stat4. The underlying mechanism has yet to be determined.
Ezh2 ablation prevents GVHD against minor histocompatibility antigens (miHAs)
To assess whether Ezh2 deficiency prevented T cell-mediated GVHD directed against miHAs, we used the MHC-identical but miHA-mismatched B6 anti-BALB.B mouse model 32 Our previous studies 33 and others 34 have shown that miHA H60-specific CD8 + effector cells (H60 + CD8 + ) possess a potent ability to mediate GVHD. WT T cells caused lethal GVHD, with approximately 80% dying from the disease (Supplemental Fig.10A ). In contrast, 90% of T-KO T cell recipients survived (Supplemental Fig.10A ). The overall expansion of donor T-KO CD8 + and CD4 + T cells was markedly reduced in these BALB.B recipients compared to that of WT T cells (Supplemental Fig.10B ). Furthermore, Ezh2 deficiency drastically decreased donor H60 + CD8 + T cells (Supplemental Fig.10C ). Thus, loss of Ezh2 prevents GVHD directed against miHAs.
Preservation of anti-leukemic effects in donor T cells in the absence of Ezh2
Donor lymphocyte infusion has been effective in treating hematological malignant diseases following transplantation. 3, 4 To determine whether donor T cells lacking Ezh2 retained the beneficial GVL, we challenged these BALB/C recipients with A20 leukemia/lymphoma cells at the day of allogeneic BMT. We tracked luciferase-expressing A20 cells using bioluminescence imaging. Mice transplanted with TCD BM and challenged with A20 cells developed leukemia and died from the disease within 36 days (Fig.7A, B) . No leukemia was found in mice receiving WT T cells, suggesting potent anti-leukemia effects. However, these WT T cell recipients died of (Fig.7A, B) . In contrast, transfer of T-KO T cells significantly reduced the growth of leukemic cells, with 30% surviving without leukemia and GVHD within the 80-day observation period (Fig.7A, B) .
To better define GVL effects of T-KO T cells, we titrated donor T cells and evaluated their ability to control leukemia growth. Transfer of 0.2x10 6 WT T cells was sufficient to eliminate leukemic cells but caused lethal GVHD (Fig.7C, D) . In contrast, as many as 0.5x10 6 T-KO T cells are necessary for significantly reducing the leukemia growth and prolonging the mean survival time of these transplant recipients (Fig.7C, D) . This suggests that T-KO T cells retain significant antileukemic activity but are less potent than WT T cells.
Since both T-KO and WT T cells had similar cytotoxicity against A20 leukemic cells (Supplemental Fig.9B ), we reasoned that increased apoptosis of alloreactive T-KO T cells could limit their GVL. To test it, we used two clinically relevant strategies to assess the anti-leukemia effect of Ezh2 inhibition in T cells. We first examined whether repetitive infusion of T-KO T cells could improve GVL effects. As compared to one injection of T-KO T cells (1x10 6 ), three injections of T-KO T cells (1x10 6 , three) at a schedule of once every 5 days after allo-BMT completely eradicated the leukemia by 28 days after infusion, with about 80% of them surviving without GVHD and leukemia (Fig.7C, D) .
We then examined whether partially reducing Ezh2 activity in donor T cells could augment
GVL effects. We titrated the number of donor T cells derived from conditional Ezh2 heterozygous knockout B6 mice (named hetero T-KO), in which only one of two Ezh2 alleles
For personal use only. on May 30, 2017 . by guest www.bloodjournal.org From was deleted in T cells. In contrast to WT T cell recipients, mice receiving 0.2x10 6 hetero T-KO cells were protected against GVHD lethality and morbidity (Supplemental Fig.11A ). Increasing the dose of hetero T-KO T cells to 1.0x10 6 caused GVHD similar to that of WT T cells (Supplemental Fig.11A ). These data suggest that the capacity of Ezh2-haploinsufficient donor T cells to mediate GVHD is markedly reduced. Importantly, infusion of 0.2x10 6 hetero T-KO cells was sufficient to eliminate leukemic cells in transplant recipients (Fig.7E, F Emerging evidence indicates that targeting epigenetic pathways can effectively prevent GVHD. For example, pharmacological inhibition of DNA methylation, which mediates global silencing of gene expression, 35 prevents acute GVHD in mice without losing GVL effects through a mechanism of modulating Tregs. 36, 37 Pharmacological inhibition of histone deacetylases (HDACs), which relaxes chromatin structure and facilitates gene transcription, 35 reduces GVHD. [38] [39] [40] Treatment with the HDAC inhibitor suberoylanilide hydroxamic acid decreases the production of inflammatory cytokines and enhances the regulatory function of APCs. [38] [39] [40] For these reasons, it is of extreme importance to identify specific chromatin modifying enzyme(s) that regulate allogeneic T-cell responses. Identification of the selective after removal of the inhibitor. 11 Thus, we propose that investigating the effect of modulating Ezh2 using specific inhibitors should consider the impact of dose, duration and time of the inhibitor and its potential off-target effects.
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1,3,4 One major reason is that cytotoxic mechanisms mediating GVHD are also important for GVL. 7 Recent studies suggest that the threshold of allogeneic T-cell responses mediating GVHD differs from that required for eliminating leukemic cells. 42, 43 For example, Notch inhibition results in dramatic reduction of multiple inflammatory cytokines and cytotoxic molecules in alloreactive T cells. 42, 44 As a result, inhibition of Notch signaling reduces GVHD but preserves potent GVL. 42, 45 Other studies also suggest that inhibition of PKC-θ, which is critical for expansion of alloreactive T cells, reduces GVHD and preserves GVL. 43 These observations support the idea that elimination of leukemic cells requires either less alloreactivity or fewer alloreactive effector T cells than induction of lethal GVHD. 46 Our findings provide a unique approach to regulate this threshold of GVH reaction, since inhibition of Ezh2 reduced GVHD while preserving GVL after allogeneic BMT.
Our observations identify Ezh2 as a new central regulator of allogeneic T-cell responses.
Ezh2 is not required for the initial activation and proliferation of alloantigen-activated T cells early during priming phase. Ezh2 is also dispensable for T cells undergoing homeostatic survival and proliferation in response to irradiation-induced lymphopenia. In contrast, Ezh2 is essential for continual proliferation, effector differentiation and expansion of alloantigen-responding T cells late during GVHD induction. Thus, our findings will be important for designing novel and clinically relevant strategies for GVHD therapies using Ezh2-specific inhibitors, which have been most recently discovered for cancer treatment in patients by other groups. [47] [48] [49] [50] 
repetitive infusion of Ezh2-deficient T cells or partial inactivation of Ezh2 function could reduce GVHD but preserve GVL, we suggest that pharmacological strategies are highly likely to be effective at improving the efficacy of allogeneic BMT. In addition, while our observations are made in mouse GVHD models, they may extend to other types of Ag-driven T-cell responses.
For instance, Ezh2 may control autoimmune diseases and rejection of allogeneic grafts. From the perspective of therapeutic point, we suggest that modulation of Ezh2 may lead to new strategies to treat other inflammatory disorders in broad context.
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